2:
Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
Barton P, Kalil AC, Nadel S, Goldstein B, Okhuysen-Cawley R, Brilli RJ, Takano JS, Martin LD, Quint P, Yeh TS, Dalton HJ, Gessouron MR, Brown KE, Betts H, Levin M, Macias WL, Small DS, Wyss VL, Bates BM, Utterback BG, Giroir BP.
Pediatrics. 2004 Jan;113(1 Pt 1):7-17.
PMID: 14702440 [PubMed - indexed for MEDLINE]
Related Articles
6:
Efficacy and safety of recombinant human activated protein C for severe sepsis.
Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group.
N Engl J Med. 2001 Mar 8;344(10):699-709.
PMID: 11236773 [PubMed - indexed for MEDLINE]
Related Articles
10:
Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.
Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R, Macias W, Wright T, Wong K, Sundin DP, Turlo MA, Janes J.
Crit Care Med. 2005 Oct;33(10):2266-77.
PMID: 16215381 [PubMed - indexed for MEDLINE]
Related Articles
16:
Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis.
Dhainaut JF, Yan SB, Margolis BD, Lorente JA, Russell JA, Freebairn RC, Spapen HD, Riess H, Basson B, Johnson G 3rd, Kinasewitz GT; PROWESS Sepsis Study Group.
Thromb Haemost. 2003 Oct;90(4):642-53.
PMID: 14515185 [PubMed - indexed for MEDLINE]
Related Articles